ABSTRACT
Objectives: A LSR is a systematic review that is continually updated, incorporating new evidence as it becomes available. They are conducted in research areas where new evidence is constantly emerging on diagnostic methods, treatments, and outcomes. The objective of this study was to understand the current application of LSRs across research areas. Method(s): Embase, MEDLINE, and the Cochrane Database of Systematic Reviews were searched to identify LSRs. Only the most recent update of a LSR was included. Data regarding the indication, intervention, methods, frequency of updates, and funding were extracted. Result(s): Of the 1,243 records identified, 126 LSRs were included for analysis. The first LSR was published in 2015, with a significant increase in the number of LSRs published starting in 2020, coinciding with the COVID-19 pandemic. The most common indication represented by LSRs was COVID-19 (72%), followed by oncology (10%). Other indications with LSRs included chronic pain, traumatic brain injury, and skin disorders, among others. While most oncology LSRs identified interventional randomized-controlled trials (RCTs) (85%), only 54% of COVID-19 LSRs were restricted to interventional studies, including a combination of RCTS and real-world observational studies. Oncology LSRs included common cancers such as prostate, renal, or multiple myeloma. Of the reviews that reported update frequency, 28% planned monthly, 12% yearly, and 12% weekly updates. Only 46% of LSRs were registered. The majority of LSRs were funded by government or research organizations. Objectives of LSRs varied, with most stating the need to maintain up-to-date databases;however, several studies used LSRs to facilitate network meta-analysis or mixed treatment comparisons. Conclusion(s): While LSRs were introduced over five years ago, their frequency increased during the COVID-19 pandemic. Apart from COVID-19, LSRs are commonly used in oncology settings. LSRs provide high-level, relevant, and up-to-date evidence, making them a useful tool for clinical and real-world research.Copyright © 2023
ABSTRACT
Objectives: Traditional systematic literature reviews (SLRs) mainly consist of indexed publications and are rarely updated, primarily relying on full-text articles to support findings. Within rapidly evolving therapeutic areas such as acute myeloid leukemia (AML), congress s can represent an expedient route to disseminate preliminary or updated trial results, as well as real-world datasets. This study aimed to describe recent trends in congress publications within AML. Methods: An SLR was performed using pre-defined search terms in accordance with PRISMA guidelines. EMBASE, MEDLINE, and Cochrane databases were systematically searched from 01/2019 to 12/2020 to identify interventional and real-world evidence (RWE) studies presented at congresses describing efficacy and safety, and studies reporting health-related quality of life (HRQoL) and economic outcomes in AML. All selected congress s were extracted and categorized using the PubTracker™ platform. Results: Of 4312 total citations published within AML in the past two years, a total of 622 (14.4%) were congress s, most frequently presented at ASH (33.3%), EHA (21.2%), EBMT (11.7%), SOHO (8.5%), TCT (4.8%), ISPOR (4.34%), ASCO (3.9%), BSH (2.57%), SIE (1.8%), and other congresses (7.88%). Three times as many s were published in 2019 (75.08%) compared to 2020 (24.92 %), likely due to the COVID-19 pandemic, where congresses were either cancelled or shifted to “virtual meetings”. Within the selected publications, most (63.5%) were real-world studies or interventional studies (25.9%), reporting efficacy and/or safety outcomes. 6.4% and 4.2% of congress s reported economic and HRQoL outcomes, respectively. Studies were mainly conducted in the United States (39.39%), and 5.31% were multi-national. Conclusions: Congress s are an important source of evidence within the dynamic landscape of AML, notably in the real-world setting. Almost half of all identified congress s within AML were presented at ASH, EHA, and EBMT, demonstrating the need for these congresses to be actively monitored.
ABSTRACT
Objectives: Although full-text articles are a primary source of evidence, s and posters presented at annual scientific meetings or congresses are an important route for disseminating current datasets, presenting a range of updated ongoing trial results to and small-scale real-world findings. This study aimed to characterize the patterns of congress publications in multiple myeloma (MM). Methods: An SLR was performed in accordance with the Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify congress s of interventional and real-world studies describing efficacy, safety, health-related quality of life (HRQoL) or economic outcomes. As such, EMBASE, MEDLINE, and Cochrane databases were searched between January 2019 and search date (31/12/2020) to identify all congress s published in the past two years, and were extracted and categorized using the PubTracker™ platform. Results: Of 3964 total citations within MM in the past two years, 618 (15.6%) were congress s, most frequently from ASH (24.9%), EHA (22%), IMW (19.6%), ISPOR (9.1%), ASCO (4.9%), BSH (3.7%), SIE (3.4%), EBMT (3.2%), TCT (2.4%), and other congresses (6.8%). Almost three times as many congress s identified were published in 2019 (71.7%) versus 2020 (28.3%), likely due to the impact of the COVID-19 pandemic producing either cancellations or “virtual meetings”. Within congress s identified, the majority (52.43%) were real-world studies, followed by interventional studies (32.04%), both reporting efficacy and safety outcomes. Congress s reporting economic and HRQoL outcomes were less frequent (10.35% and 5.18%, respectively). Studies were mainly conducted in the USA (29.10%), and 5.66% were multi-national. Conclusions: Congress s are an important source of evidence within the ever-changing therapeutic landscape of MM and are increasingly utilized to disseminate data obtained in the real-world setting. Almost half of all identified congress s were presented at ASH, EHA, and IMW, demonstrating the need for these congresses to be closely tracked.